United States

People: Henry Schein Inc (HSIC.OQ)

HSIC.OQ on NASDAQ Stock Exchange Global Select Market

24 May 2019
Change (% chg)

$-0.65 (-0.96%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sheares, Bradley 

Dr. Bradley T. Sheares, Ph.D. serves as Independent Director of the Company. Dr. Sheares served as Chief Executive Officer of Reliant Pharmaceuticals, Inc., from January 2007 through its acquisition by GlaxoSmithKline plc in December 2007. Prior to joining Reliant, from 2001 until 2006, Dr. Sheares served as President of U.S. Human Health for Merck & Co. As a member of Merck’s management committee, Dr. Sheares had responsibility for formulating global business strategies, operations management and the development and implementation of corporate policies. He is also a director of Honeywell International (and is a member of its management development and compensation committee and retirement plan committee) and is a director and Chairman of the compensation committee of The Progressive Corporation. As the former Chief Executive Officer of Reliant Pharmaceuticals and with 20 years in the pharmaceutical industry (part of our medical and animal health businesses), Dr. Sheares brings to the Company’s Board of Directors extensive health care knowledge and experience in sales, marketing, brand management, research and development, complex regulatory and legal issues, risk management and mergers and acquisitions. As a director of other public companies, Dr. Sheares has been involved in succession planning, compensation, employee management and the evaluation of acquisition opportunities. During the past five years, Dr. Sheares served as a director of Covance Inc.

Basic Compensation

Total Annual Compensation, USD 96,777
Restricted Stock Awards, USD 185,400
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 282,177

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --